2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …
Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …
MJ Davies, VR Aroda, BS Collins, RA Gabbay… - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the previous consensus statements on the management of …
convened a panel to update the previous consensus statements on the management of …
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the …
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the previous consensus statements on the …
Diabetes convened a panel to update the previous consensus statements on the …
Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the …
CSP Lam, C Ramasundarahettige, KRH Branch… - Circulation, 2022 - Am Heart Assoc
Background: Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like
peptide-1 receptor agonists reduce cardiovascular events among patients with type 2 …
peptide-1 receptor agonists reduce cardiovascular events among patients with type 2 …
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus …
Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
[HTML][HTML] The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and …
C Li, J Luo, M Jiang, K Wang - Frontiers in Pharmacology, 2022 - frontiersin.org
Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2
inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims …
inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims …
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
JS Moon, JH Hong, YJ Jung, E Ferrannini… - Trends in Endocrinology …, 2022 - cell.com
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that
affects nearly one billion people globally, characterized by triacylglycerol accumulation in …
affects nearly one billion people globally, characterized by triacylglycerol accumulation in …
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …
SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD
M Ala - Endocrinology, 2021 - academic.oup.com
Abstract Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …
Repurposing antidiabetic drugs for cardiovascular disease
M Schubert, S Hansen, J Leefmann, K Guan - Frontiers in physiology, 2020 - frontiersin.org
Metabolic diseases and diabetes represent an increasing global challenge for human health
care. As associated with a strongly elevated risk of developing atherosclerosis, kidney …
care. As associated with a strongly elevated risk of developing atherosclerosis, kidney …